Cargando…

γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers

BACKGROUND: Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. METHODS: DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-wel...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Shibo, Yang, Ying, Tirtha, Das, Yen, Yun, Zhou, Bing-sen, Zhou, Ming-Ming, Ohlmeyer, Michael, Ko, Eric C., Cagan, Ross, Rosenstein, Barry S., Chen, Shu-hsia, Kao, Johnny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387170/
https://www.ncbi.nlm.nih.gov/pubmed/22768044
http://dx.doi.org/10.1371/journal.pone.0038465
_version_ 1782237066411638784
author Fu, Shibo
Yang, Ying
Tirtha, Das
Yen, Yun
Zhou, Bing-sen
Zhou, Ming-Ming
Ohlmeyer, Michael
Ko, Eric C.
Cagan, Ross
Rosenstein, Barry S.
Chen, Shu-hsia
Kao, Johnny
author_facet Fu, Shibo
Yang, Ying
Tirtha, Das
Yen, Yun
Zhou, Bing-sen
Zhou, Ming-Ming
Ohlmeyer, Michael
Ko, Eric C.
Cagan, Ross
Rosenstein, Barry S.
Chen, Shu-hsia
Kao, Johnny
author_sort Fu, Shibo
collection PubMed
description BACKGROUND: Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. METHODS: DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of γ-H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and biochemical assays and in vivo activity was tested in a validated Drosophila cancer model. RESULTS: We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of γ-H2AX, apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity. CONCLUSIONS: MS0019266 and MS0017509 are promising compounds that may be candidates for further development as radiosensitizing compounds as inhibitors of ribonucleotide reductase.
format Online
Article
Text
id pubmed-3387170
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33871702012-07-05 γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers Fu, Shibo Yang, Ying Tirtha, Das Yen, Yun Zhou, Bing-sen Zhou, Ming-Ming Ohlmeyer, Michael Ko, Eric C. Cagan, Ross Rosenstein, Barry S. Chen, Shu-hsia Kao, Johnny PLoS One Research Article BACKGROUND: Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. METHODS: DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of γ-H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and biochemical assays and in vivo activity was tested in a validated Drosophila cancer model. RESULTS: We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of γ-H2AX, apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity. CONCLUSIONS: MS0019266 and MS0017509 are promising compounds that may be candidates for further development as radiosensitizing compounds as inhibitors of ribonucleotide reductase. Public Library of Science 2012-06-29 /pmc/articles/PMC3387170/ /pubmed/22768044 http://dx.doi.org/10.1371/journal.pone.0038465 Text en Fu et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Fu, Shibo
Yang, Ying
Tirtha, Das
Yen, Yun
Zhou, Bing-sen
Zhou, Ming-Ming
Ohlmeyer, Michael
Ko, Eric C.
Cagan, Ross
Rosenstein, Barry S.
Chen, Shu-hsia
Kao, Johnny
γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers
title γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers
title_full γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers
title_fullStr γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers
title_full_unstemmed γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers
title_short γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers
title_sort γ-h2ax kinetics as a novel approach to high content screening for small molecule radiosensitizers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387170/
https://www.ncbi.nlm.nih.gov/pubmed/22768044
http://dx.doi.org/10.1371/journal.pone.0038465
work_keys_str_mv AT fushibo gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT yangying gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT tirthadas gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT yenyun gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT zhoubingsen gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT zhoumingming gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT ohlmeyermichael gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT koericc gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT caganross gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT rosensteinbarrys gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT chenshuhsia gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers
AT kaojohnny gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers